samedan logo

home > ict > autumn 2019 > the pacific rim
International Clinical Trials

The Pacific Rim

In the US and EU, approximately 35% of trial delays occur as a result of patient recruitment, and one-fifth of the trials in these countries do not enrol a sufficient number of subjects. Shown in Figure 1, to expedite the recruitment process and avoid drug approval delays, both the US and EU have increased their number of registered clinical trials in developed Asian countries such as Japan, South Korea, China, India, and Malaysia (1).

It is well known that the primary barriers to conducting clinical trials in the US and Western Europe involve challenges in participant recruitment and retention, resulting in longer lead times and high costs (2). Furthermore, contracting qualified and experienced investigators and key opinion leaders add to the already lengthy trial times (3).

A 2013 analysis found that almost 57% of trials fail due to low patient accrual rates, which could translate into huge financial losses (4). Adding to this recruitment problem, racial and ethnic minorities, women, and the elderly are often under-represented in enrolments. For example, a study found that only 25% of elderly cancer patients enrol in trials, although they account for 63% of new cancer cases (5).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the author

As Chief Medical Officer of Linical Accelovance Group, Dr Tracy Goeken is responsible for providing strategic and operational leadership regarding the company’s global medical and scientific operations. Dr Goeken oversees clinical development functions and activities within the company, including medical, regulatory, medical writing, and pre- and post-market pharmacovigilance departments ensuring global alignment and operational excellence. Tracy received his MD from St. Christopher’s College of Medicine, UK, having completed his clinical training at LSU Health Sciences Center in Louisiana.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Connectivity, customization and sustainability driving packaging and drug delivery in 2020

Paris, 03 December 2019: Connectivity, customization and sustainability are driving pharmaceutical packaging and drug delivery innovation at Pharmapack Europe (#pharmapackeu), which opens in February 2020. The event is the leading exhibition dedicated to pharmaceutical packaging and drug delivery devices, with major industry players set to come together to discuss vital best practices, insights and strategies.
More info >>

White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

Industry Events

World Vaccine Congress Washington

7-9 April 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement